[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585924":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":29,"locations":40,"responsibleParty":63,"collaborators":65,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":34,"enrollmentInfo":78,"targetDuration":34,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":42,"whyStopped":34,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Hamilton Health Sciences Corporation","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Semaglutide","EXPERIMENTAL","The semaglutide dose will be 0.25mg subcutaneously once weekly for weeks 1-4, then 0.5mg once weekly for weeks 5-8, then 1mg once weekly for weeks 9-12, then 1.7mg once weekly for weeks 13-16, and then 2.4mg for the remainder of the trial. Semaglutide dose may be decreased in the case of adverse events to the highest tolerated dose.",[13],"Drug: Semaglutide Pen Injector",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Semaglutide Pen Injector",[9],[20],"Wegovy®",[22,26],{"name":23,"affiliation":24,"role":25},"Darryl Leong, MBBs,MPH,PhD,FRACP,FESC","Population Health Research Institute and McMaster University","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":28,"role":25},"Jehonathan Pinthus, MD,FRCS(C),PhD","Juravinski Cancer Centre",[30,36],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Sarah Karampatos, BASc, MSc","CONTACT","905-296-5795",null,"sarah.karampatos@phri.ca",{"name":37,"role":32,"phone":38,"phoneExt":34,"email":39},"Steven Agapay, BSc","905-296-5764","steve.agapay@phri.ca",[41],{"facility":28,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Hamilton","Ontario","L8V1C3","Canada","CA",{"type":49,"coordinates":50},"Point",[51,52],-79.84963,43.25011,{"lat":52,"lon":51},[55,58,61,62],{"name":56,"role":32,"phone":34,"phoneExt":34,"email":57},"Nadra Yasmin","nadra.yasmin@phri.ca",{"name":59,"role":32,"phone":34,"phoneExt":34,"email":60},"Shauna Szendrey","szendreys@hhsc.ca",{"name":23,"role":25,"phone":34,"phoneExt":34,"email":34},{"name":27,"role":25,"phone":34,"phoneExt":34,"email":34},{"type":64,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR",[66],{"name":67,"class":6},"McMaster University","100585924","phase-4-investigation-of-glp1-receptor-agonists-in-men-with-prostate-cancer-taking-androgen-deprivation-therapy-100585924",false,"NCT06908694","Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy","GLP1-Receptor Agonists in Men With Prostate Cancer: Control of Cardiovascular Risk Factors and Prostate Biomarkers","GAINPCCONTROL","Inclusion Criteria:\n\n* Have a physician diagnosis of PC\n* Must be receiving or planned to receive ADT (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor)\n* Elevated BMI\n\n  1. ≥30kg\u002Fm2 or\n  2. ≥27kg\u002Fm2 in the presence of at least one of hypertension, type 2 diabetes, obstructive sleep apnea or dyslipidemia\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* Taking a GLP-1 RA\n* \\\u003C18 years of age\n* History of pancreatitis\n* Personal or family history of medullary cancer of the thyroid\n* Multiple endocrine neoplasia type 2","MALE","18 Years",{"count":79,"type":80},20,"ESTIMATED","INTERVENTIONAL",[83],"PHASE4","GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.",[86],"Prostate Cancer",[88,89],"Androgen Deprivation Therapy","GLP-1 Receptor Agonists","2025-07-25",{"date":92,"type":93},"2025-07-29","ACTUAL",{"date":95,"type":93},"2025-07-02",{"date":97,"type":80},"2026-07-31",{"name":5,"class":6},1]